Vaccibody As Top Management
VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody employs about 33 people. The company is managed by 10 executives with a total tenure of roughly 77 years, averaging almost 7.0 years of service per executive, having 3.3 employees per reported executive. Evaluation of Vaccibody's management performance can provide insight into the firm performance.
Gemma Brown Insider Chief Officer |
Bernie McDonald Insider Head IP |
Vaccibody |
Vaccibody Management Team Effectiveness
The company has return on total asset (ROA) of (0.152) % which means that it has lost $0.152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2329) %, meaning that it created substantial loss on money invested by shareholders. Vaccibody's management efficiency ratios could be used to measure how well Vaccibody manages its routine affairs as well as how well it operates its assets and liabilities.Vaccibody Workforce Comparison
Vaccibody As is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,522. Vaccibody claims roughly 33.0 in number of employees contributing just under 2% to equities under Health Care industry.
Vaccibody Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccibody insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccibody's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vaccibody insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scheeren Joseph over a year ago Purchase by Scheeren Joseph of 10000 shares of Vaccitech PLC | ||
Wright Robin over a year ago Purchase by Wright Robin of 13750 shares of Vaccitech PLC | ||
Enright William over a year ago Sale by Enright William of 15000 shares of Vaccitech PLC | ||
Pelletier Nadege over a year ago Acquisition by Pelletier Nadege of 485000 shares of Vaccitech PLC subject to Rule 16b-3 | ||
Chris Ellis over a year ago Acquisition by Chris Ellis of 105000 shares of Vaccitech PLC subject to Rule 16b-3 | ||
Hammacher Alex over a year ago Acquisition by Hammacher Alex of 18604 shares of Vaccitech PLC subject to Rule 16b-3 |
Vaccibody Notable Stakeholders
A Vaccibody stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaccibody often face trade-offs trying to please all of them. Vaccibody's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaccibody's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gemma Brown | Chief Officer | Profile | |
Bernie McDonald | Head IP | Profile | |
William MBA | CEO Director | Profile | |
Margaret MD | Chief Officer | Profile | |
Adrian Hill | CoFounder Advisor | Profile | |
Sarah Gilbert | CoFounder | Profile | |
Chris Ellis | Chief Officer | Profile | |
Graham Griffiths | Chief Officer | Profile | |
Thomas MD | Chief Officer | Profile | |
Elizabeth MBA | Head Operations | Profile |
About Vaccibody Management Performance
The success or failure of an entity such as Vaccibody As often depends on how effective the management is. Vaccibody management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaccibody management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaccibody management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Please note, the presentation of Vaccibody's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vaccibody's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vaccibody's management manipulating its earnings.
Vaccibody Workforce Analysis
Traditionally, organizations such as Vaccibody use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaccibody within its industry.Vaccibody Manpower Efficiency
Return on Vaccibody Manpower
Revenue Per Employee | 1.4M | |
Revenue Per Executive | 4.5M | |
Net Income Per Employee | 161.2K | |
Net Income Per Executive | 532.1K | |
Working Capital Per Employee | 6.1M | |
Working Capital Per Executive | 20.1M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |